Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice

Journal of Comparative Neurology

Volumn 522, Issue 6, 2014, Pages 1390-1410

  Kelley, Christy M ^a   Powers, Brian E ^b   Velazquez, Ramon ^b   Ash, Jessica A ^b   Ginsberg, Stephen D ^c,d   Strupp, Barbara J ^b   Mufson, Elliott J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Molecular Biology and Genetics   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Choline acetyltransferase; Diagonal band; Down syndrome; Medial septum; Nucleus basalis; P75 neurotrophin receptor

Indexed keywords

CHOLINE; CHOLINE ACETYLTRANSFERASE; NEUROTROPHIN RECEPTOR P75; PARAFORMALDEHYDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL COUNT; CELL DENSITY; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOWN SYNDROME; FEMALE; FOREBRAIN; GENOTYPE; IMMUNOHISTOCHEMISTRY; MATERNAL NUTRITION; MORPHOMETRICS; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROGENY; WEANING; YOUNG ADULT;

CHOLINE ACETYLTRANSFERASE; DIAGONAL BAND; DOWN SYNDROME; MEDIAL SEPTUM; NUCLEUS BASALIS; P75 NEUROTROPHIN RECEPTOR;

AGE FACTORS; ANIMALS; CELL COUNT; CELL SIZE; CHOLINE; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC FIBERS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; MALE; MATERNAL EXPOSURE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PREGNANCY; PROSENCEPHALON; RECEPTORS, NERVE GROWTH FACTOR;

EID: 84896031573     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.23492     Document Type: Article

References (131)

1. Akeson EC, Lambert JP, Narayanswami S, Gardiner K, Bechtel LJ, Davisson MT. 2001. Ts65Dn-localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome. Cytogenet Cell Genet 93:270-276.
2. Armstrong DM, Bruce G, Hersh LB, Gage FH. 1987. Development of cholinergic neurons in the septal/diagonal band complex of the rat. Brain Res 433:249-256.
3. Becker L, Mito T, Takashima S, Onodera K. 1991. Growth and development of the brain in Down syndrome. Prog Clin Biol Res 373:133-152.
4. Berger-Sweeney J, Stearns NA, Murg SL, Floerke-Nashner LR, Lappi DA, Baxter MG. 2001. Selective immunolesions of cholinergic neurons in mice: effects on neuroanatomy, neurochemistry, and behavior. J Neurosci 21:8164-8173.
5. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. 1995. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 64:749-760.
6. Blusztajn JK, Cermak JM, Holler T, Jackson DA. 1998. Imprinting of hippocampal metabolism of choline by its availability during gestation: implications for cholinergic neurotransmission. J Physiol Paris 92:199-203.
7. Brady DR, Phelps PE, Vaughn JE. 1989. Neurogenesis of basal forebrain cholinergic neurons in rat. Brain Res Dev Brain Res 47:81-92.
8. Casanova MF, Walker LC, Whitehouse PJ, Price DL. 1985. Abnormalities of the nucleus basalis in Down's syndrome. Ann Neurol 18:310-313.
9. Cataldo AM, Petanceska S, Peterhoff CM, Terio NB, Epstein CJ, Villar A, Carlson EJ, Staufenbiel M, Nixon RA. 2003. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci 23:6788-6792.
10. Cermak JM, Holler T, Jackson DA, Blusztajn JK. 1998. Prenatal availability of choline modifies development of the hippocampal cholinergic system. FASEB J 12:349-357.
11. Cermak JM, Blusztajn JK, Meck WH, Williams CL, Fitzgerald CM, Rosene DL, Loy R. 1999. Prenatal availability of choline alters the development of acetylcholinesterase in the rat hippocampus. Dev Neurosci 21:94-104.
12. Chen Y, Dyakin VV, Branch CA, Ardekani B, Yang D, Guilfoyle DN, Peterson J, Peterhoff C, Ginsberg SD, Cataldo AM, Nixon RA. 2009. In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. Neurobiol Aging 30:1453-1465.
13. Contestabile A, Fila T, Bartesaghi R, Contestabile A, Ciani E. 2006. Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. J Neurochem 97:515-526.
14. Cooney CA, Dave AA, Wolff GL. 2002. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J Nutr 132:2393S-2400S.
15. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC. 2001. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A 98:10439-10444.
16. Costa AC, Scott-McKean JJ, Stasko MR. 2008. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33:1624-1632.
17. Cotman C, Gentry C, Steward O. 1977. Synaptic replacement in the dentate gyrus after unilateral entorhinal lesion: electron microscopic analysis of the extent of replacement of synapses by the remaining entorhinal cortex. J Neurocytol 6:455-464.
18. Counts SE, Mufson EJ. 2005. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer's disease. J Neuropathol Exp Neurol 64:263-272.
19. Coyle JT, Oster-Granite ML, Reeves RH, Gearhart JD. 1988. Down syndrome, Alzheimer's disease and the trisomy 16 mouse. Trends Neurosci 11:390-394.
20. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. 1999. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281:1401-1406.
21. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ. 2002. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145-155.
22. Detopoulou P, Panagiotakos DB, Antonopoulou S, Pitsavos C, Stefanadis C. 2008. Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study. Am J Clin Nutr 87:424-430.
23. Epstein CJ. 1995. Epilogue: toward the twenty-first century with Down syndrome-a personal view of how far we have come and of how far we can reasonably expect to go. Prog Clin Biol Res 393:241-246.
24. Fisher MC, Zeisel SH, Mar MH, Sadler TW. 2001. Inhibitors of choline uptake and metabolism cause developmental abnormalities in neurulating mouse embryos. Teratology 64:114-122.
25. Fisher MC, Zeisel SH, Mar MH, Sadler TW. 2002. Perturbations in choline metabolism cause neural tube defects in mouse embryos in vitro. FASEB J 16:619-621.
26. Gardiner K, Fortna A, Bechtel L, Davisson MT. 2003. Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 318:137-147.
27. Ginsberg SD. 2005. Glutamatergic neurotransmission expression profiling in the mouse hippocampus after perforant-path transection. Am J Geriatr Psychiatry 13:1052-1061.
28. NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 97:475-487.
29. Glasser J, Greene G, Hendricks S. 2007. Stereology for biological research with a focus on neuroscience. Williston, VT: MBF Press.
30. Gossell-Williams M, Fletcher H, McFarlane-Anderson N, Jacob A, Patel J, Zeisel S. 2005. Dietary intake of choline and plasma choline concentrations in pregnant women in Jamaica. West Indian Med J 54:355-359.
31. Granholm AC, Sanders LA, Crnic LS. 2000. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol 161:647-663.
32. Granholm AC, Ford KA, Hyde LA, Bimonte HA, Hunter CL, Nelson M, Albeck D, Sanders LA, Mufson EJ, Crnic LS. 2002. Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol Behav 77:371-385.
33. Gundersen HJ. 1988. The nucleator. J Microsc 151:3-21.
34. Gundersen HJ, Jensen EB, Kiêu K, Nielsen J. 1999. The efficiency of systematic sampling in stereology-reconsidered. J Microsc 193:199-211.
35. Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C, on behalf of the MEADOWS trial researchers. 2012. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 379:528-536.
36. Hasselmo ME, Sarter M. 2011. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 36:52-73.
37. Hayes A, Batshaw ML. 1993. Down syndrome. Pediatr Clin North Am 40:523-535.
38. Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, Kishnani PS. 2004. Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial. Am J Med Genet A 130A:325-326.
39. Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH. 1995. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol 52:379-391.
40. Holler T, Cermak JM, Blusztajn JK. 1996. Dietary choline supplementation in pregnant rats increases hippocampal phospholipase D activity of the offspring. FASEB J 10:1653-1659.
41. Holmes GL, Yang Y, Liu Z, Cermak JM, Sarkisian MR, Stafstrom CE, Neill JC, Blusztajn JK. 2002. Seizure-induced memory impairment is reduced by choline supplementation before or after status epilepticus. Epilepsy Res 48:3-13.
42. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC. 1996. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A 93:13333-13338.
43. Hunter CL, Isacson O, Nelson M, Bimonte-Nelson H, Seo H, Lin L, Ford K, Kindy MS, Granholm AC. 2003. Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome. Neurosci Res 45:437-445.
44. Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett DA, DeKosky ST. 2003. Cholinergic plasticity in the hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis 5:39-48.
45. Jensen HH, Batres-Marquez SP, Carriquiry A, Schalinske KL. 2007. Choline in the diets of the US population: NHANES, 2003-2004. FASEB J 21:lb219.
46. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. 2003. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard 108:367-372.
47. Jørgensen OS, Brooksbank BW, Balázs R. 1990. Neuronal plasticity and astrocytic reaction in Down syndrome and Alzheimer disease. J Neurol Sci 98:63-79.
48. Kahlem P, Sultan M, Herwig R, Steinfath M, Balzereit D, Eppens B, Saran NG, Pletcher MT, South ST, Stetten G, Lehrach H, Reeves RH, Yaspo ML. 2004. Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of Down syndrome. Genome Res 14:1258-1267.
49. Keeler C. 1966. Retinal degeneration in the mouse is rodless retina. J Hered 57:47-50.
50. Kelley CM, Perez SE, Overk CR, Wynick D, Mufson EJ. 2011. Effect of neocortical and hippocampal amyloid deposition upon galaninergic and cholinergic neurites in AβPPswe/PS1ΔE9 mice. J Alzheimers Dis 25:491-504.
51. Kelley CM, Powers BE, Velazquez R, Ash JA, Ginsberg SD, Strupp BJ, Mufson EJ. 2013. Sex differences in cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease. Brain Pathol, Epub doi 10.11/bra.
52. Kish S, Karlinsky H, Becker L, Gilbert J, Rebbetoy M, Chang LJ, DiStefano L, Hornykiewicz O. 1989. Down's syndrome individuals begin life with normal levels of brain cholinergic markers. J Neurochem 52:1183-1187.
53. Kishnani PS, Sommer BR, Handen BL, Seltzer B, Capone GT, Spiridigliozzi GA, Heller JH, Richardson S, McRae T. 2009. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am J Med Genet A 149A:1641-1654.
54. Koh S, Loy R. 1989. Localization and development of nerve growth factor-sensitive rat basal forebrain neurons and their afferent projections to hippocampus and neocortex. J Neurosci 9:2999-3018.
55. Kondoh T, Kanno A, Itoh H, Nakashima M, Honda R, Kojima M, Noguchi M, Nakane H, Nozaki H, Sasaki H, Nagai T, Kosaki R, Kakee N, Okuyama T, Fukuda M, Ikeda M, Shibata Y, Moriuchi H. 2011. Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial. Int J Psychiatry Med 41:71-89.
56. Kovacheva VP, Mellott TJ, Davison JM, Wagner N, Lopez-Coviella I, Schnitzler AC, Blusztajn JK. 2007. Gestational choline deficiency causes global and Igf2 gene DNA hypermethylation by up-regulation of Dnmt1 expression. J Biol Chem 282:31777-31788.
57. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357.
58. Levey AI, Armstrong DM, Atweh SF, Terry RD, Wainer BH. 1983. Monoclonal antibodies to choline acetyltransferase: production, specificity, and immunohistochemistry. J Neurosci 3:1-9.
59. Li Q, Guo-Ross S, Lewis DV, Turner D, White AM, Wilson WA, Swartzwelder HS. 2004. Dietary prenatal choline supplementation alters postnatal hippocampal structure and function. J Neurophysiol 91:1545-1555.
60. Liang Z, Liu F, Iqbal K, Grundke-Iqbal I, Wegiel J, Gong CX. 2008. Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J Alzheimers Dis 13:295-302.
61. Liu DP, Schmidt C, Billings T, Davisson MT. 2003. Quantitative PCR genotyping assay for the Ts65Dn mouse model of Down syndrome. Biotechniques 35:1170-1174.
62. Lockrow J, Prakasam A, Huang P, Bimonte-Nelson H, Sambamurti K, Granholm AC. 2009. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol 216:278-272.
63. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. 2011. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 221:610-622.
64. Lott IT, Osann K, Doran E, Nelson L. 2002. Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol 59:1133-1136.
65. Loy R, Heyer D, Williams CL, Meck WH. 1991. Choline-induced spatial memory facilitation correlates with altered distribution and morphology of septal neurons. Adv Exp Med Biol 295:373-382.
66. Määttä T, Kaski M, Taanila A, Keinänen-Kiukaanniemi S, Iivanainen M. 2006. Sensory impairments and health concerns related to the degree of intellectual disability in people with Down syndrome. Downs Syndr Res Pract 11:78-83.
67. Mann DM, Yates PO, Marcyniuk B. 1984. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol 10:185-207.
68. Margallo-Lana M, Morris CM, Gibson AM, Tan AL, Kay DW, Tyrer SP, Moore BP, Ballard CG. 2004. Influence of the amyloid precursor protein locus on dementia in Down syndrome. Neurology 62:1996-1998.
69. McGeer EG, Norman M, Boyes B, O'Kusky J, Suzuki J, McGeer PL. 1985. Acetylcholine and aromatic amine systems in postmortem brain of an infant with Down's syndrome. Exp Neurol 87:557-570.
70. McKeon-O'Malley C, Siwek D, Lamoureux JA, Williams CL, Kowall NW. 2003. Prenatal choline deficiency decreases the cross-sectional area of cholinergic neurons in the medial septal nucleus. Brain Res 977:278-283.
71. Meck WH, Williams CL. 1997. Characterization of the facilitative effects of perinatal choline supplementation on timing and temporal memory. Neuroreport 8:2831-2835.
72. Meck WH, Williams CL. 1999. Choline supplementation during prenatal development reduces proactive interference in spatial memory. Brain Res Dev Brain Res 118:51-59.
73. Meck WH, Williams CL. 2003. Metabolic imprinting of choline by its availability during gestation: implications for memory and attentional processing across the lifespan. Neurosci Biobehav Rev 27:385-399.
74. Meck WH, Smith RA, Williams CL. 1988. Pre- and postnatal choline supplementation produces long-term facilitation of spatial memory. Dev Psychobiol 21:339-353.
75. Meck WH, Smith RA, Williams CL. 1989. Organizational changes in cholinergic activity and enhanced visuospatial memory as a function of choline administered prenatally or postnatally or both. Behav Neurosci 103:1234-1241.
76. Meck WH, Williams CL, Cermak JM, Blusztajn JK. 2007. Developmental periods of choline sensitivity provide an ontogenetic mechanism for regulating memory capacity and age-related dementia. Front Integr Neurosci 1:7.
77. Mellott TJ, Williams CL, Meck WH, Blusztajn JK. 2004. Prenatal choline supplementation advances hippocampal development and enhances MAPK and CREB activation. FASEB J 18:545-547.
78. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. 1983. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214:170-197.
79. Mohan M, Bennett C, Carpenter PK. 2009. Memantine for dementia in people with Down syndrome. Cochrane Database Syst Rev CD007657.
80. Moon J, Chen M, Gandhy SU, Strawderman M, Levitsky DA, Maclean KN, Strupp BJ. 2010. Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. Behav Neurosci 124:346-361.
81. Mouton PR. 2002. Principles and practices of unbiased stereology: an introduction for bioscientists. Baltimore, MD: Johns Hopkins University Press.
82. Mufson EJ, Bothwell M, Kordower JH. 1989. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol 105:221-232.
83. Myers BA, Pueschel SM. 1991. Psychiatric disorders in persons with Down syndrome. J Nerv Ment Dis 179:609-613.
84. Nadler JV, Cotman CW, Lynch G. 1977. Histochemical evidence of altered development of cholinergic fibers in the rat dentate gyrus following lesions. I. Time course after complete unilateral entorhinal lesion at various ages. J Comp Neurol 171:561-587.
85. Nag N, Berger-Sweeney JE. 2007. Postnatal dietary choline supplementation alters behavior in a mouse model of Rett syndrome. Neurobiol Dis 26:473-480.
86. Nag N, Mellott TJ, Berger-Sweeney JE. 2008. Effects of postnatal dietary choline supplementation on motor regional brain volume and growth factor expression in a mouse model of Rett syndrome. Brain Res 1237:101-109.
87. National Academy of Sciences and Institute of Medicine (IOM). 1998. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press.
88. Niculescu MD, Yamamuro Y, Zeisel SH. 2004. Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene. J Neurochem 89:1252-1259.
89. Overk CR, Kelley CM, Mufson EJ. 2009. Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis 35:415-425.
90. Paxinos G, Franklin KBJ. 2001. The mouse brain in stereotaxic coordinate, 2nd ed. San Diego, CA: Academic Press.
91. Pogribny IP, Karpf AR, James SR, Melnyk S, Han T, Tryndyak VP. 2008. Epigenetic alterations in the brains of Fisher 344 rats induced by long-term administration of folate/methyl-deficient diet. Brain Res 1237:25-34.
92. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC. 1998. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 43:380-383.
93. Prasher VP, Huxley A, Haque MS; Down syndrome Ageing Study Group. 2002. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease-pilot study. Int J Geriatr Psychiatry 17:270-278.
94. Pyapali GK, Turner DA, Williams CL, Meck WH, Swartzwelder HS. 1998. Prenatal dietary choline supplementation decreases the threshold for induction of long-term potentiation in young adult rats. J Neurophysiol 79:1790-1796.
95. Raghanti MA, Stimpson CD, Marcinkiewicz JL, Erwin JM, Hof PR, Serwood CC. 2008. Cholinergic innervation of the frontal cortex: differences among humans, chimpanzees, and macaque monkeys. J Comp Neurol 506:409-424.
96. Rasband WS. 1997-2012. Image J. Bethesda, MD: U.S. National Institutes of Health. http://imagej.nih.gov/ij/.
97. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, Schmidt C, Bronson RT, Davisson MT. 1995. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11:177-184.
98. Roper RJ, St John HK, Philip J, Lawler A, Reeves RH. 2006. Perinatal loss of Ts65Dn Down syndrome mice. Genetics 172:437-443.
99. Rye DB, Wainer BH, Mesulam MM, Mufson EJ, Saper CB. 1984. Cortical projections arising from the basal forebrain: a study of cholinergic and noncholinergic components employing combined retrograde tracing and immunohistochemical localization of choline acetyltransferase. Neuroscience 13:627-643.
100. Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kulnane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC. 2006. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51:29-42.
101. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M, Mobley WC. 2009. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 1:7-17.
102. Sandstrom NJ, Loy R, Williams CL. 2002. Prenatal choline supplementation increases NGF levels in the hippocampus and frontal cortex of young and adult rats. Brain Res 947:9-16.
103. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, Kurz A. 2010. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement 6:1-10.
104. Schenk F, Brandner C. 1995. Indirect effects of peri- and postnatal choline treatment on place-learning abilities in rat. Psychobiology 23:302-313.
105. Semba K, Fibiger HC. 1988. Time of origin of cholinergic neurons in the rat basal forebrain. J Comp Neurol 269:87-95.
106. Sendera TJ, Ma SY, Jaffar S, Kozlowski PB, Kordower JH, Mawal Y, Saragovi HU, Mufson EJ. 2000. Reduction in TrkA-immunoreactive neurons is not associated with an overexpression of galaninergic fibers within the nucleus basalis in Down's syndrome. J Neurochem 74:1185-1196.
107. Seo H, Isacson O. 2005. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp Neurol 193:469-480.
108. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866-2875.
109. Shaw GM, Carmichael SL, Yang W, Selvin S, Schaffer DM. 2004. Periconceptional dietary intake of choline and betaine and neural tube defects in offspring. Am J Epidemiol 160:102-109.
110. Signore C, Ueland PM, Troendle J, Mills JL. 2008. Choline concentrations in human maternal and cord blood and intelligence at 5 y of age. Am J Clin Nutr 87:896-902.
111. Spiridigliozzi GA, Heller JH, Crissman BG, Sullivan-Saarela JA, Eells R, Dawson D, Li J, Kishnani PS. 2007. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. Am J Med Genet A 143A:1408-1413.
112. Stereology Resource Center. 2008. Applications of unbiased stereology to neural systems. Kent Island, MD.
113. Steward O, Vinsant SL, Davis L. 1988. The process of reinnervation in the dentate gyrus of adult rats: an untrastructural study of changes in presynaptic terminals as a result of sprouting. J Comp Neurol 267:203-210.
114. Tees RC. 1999. The influences of rearing environment and neonatal choline dietary supplementation on spatial learning and memory in adult rats. Behav Brain Res 105:173-188.
115. Thomas JD, Biane JS, O'Bryan KA, O'Neill TM, Dominguez HD. 2007. Choline supplementation following third-trimester-equivalent alcohol exposure attenuates behavioral alterations in rats. Behav Neurosci 121:120-130.
116. Thomas JD, Abou EJ, Dominguez HD. 2009. Prenatal choline supplementation mitigates the adverse effects of prenatal alcohol exposure on development in rats. Neurotoxicol Teratol 31:303-311.
117. Velazquez R Ash JA, Powers BE, Kelley CM, Strawderman M, Luscher Z, Ginsberg SD, Mufson EJ, Strupp BJ. 2013. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 52C:92-101.
118. Vilardell M, Rasche A, Thormann A, Maschke-Dutz E, Pérez-Jurado LA, Lehrach H, Herwig R. 2011. Meta-analysis of heterogeneous Down syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics 12:229.
119. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
120. Ward BC, Agarwal S, Wang K, Berger-Sweeney J, Kolodny NH. 2008. Longitudinal brain MRI study in a mouse model of Rett syndrome and the effects of choline. Neurobiol Dis 31:110-119.
121. Waterland RA, Jirtle RL. 2003. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 23:5293-5300.
122. Wegiel J, Wisniewski HM, Dziewiatkowski J, Popovitch ER, Tarnawski M. 1996. Differential susceptibility to neurofibrillary pathology among patients with Down syndrome. Dementia 7:135-141.
123. Wegiel J, Gong CX, Hwang YW. 2011. The role of DYRK1A in neurodegenerative diseases. FEBS J 278:236-245.
124. Williams CL, Meck WH, Heyer DD, Loy R. 1998. Hypertrophy of basal forebrain neurons and enhanced visuospatial memory in perinatally choline-supplemented rats. Brain Res 794:225-238.
125. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. 1985. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 35:957-961.
126. Wong-Goodrich SJ, Glenn MJ, Mellott TJ, Blusztajn JK, Meck WH, Williams CL. 2008. Spatial memory and hippocampal plasticity are differentially sensitive to the availability of choline in adulthood as a function of choline supply in utero. Brain Res 1237:153-166.
127. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH. 2009. Administration of docosahexaenoic acid, uridine and choline increases levels of synaptic membranes and dendritic spines in rodent brain. World Rev Nutr Diet 99:71-96.
128. Yates CM, Simpson J, Maloney AF, Gordon A, Reid AH. 1980. Alzheimer-like cholinergic deficiency in Down syndrome. Lancet 2:979.
129. Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, Urquhart A. 1983. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 280:119-126.
130. Zeisel SH. 2000. Choline: an essential nutrient for humans. Nutrition 16:669-671.
131. Zeisel SH, Blusztajn JK. 1994. Choline and human nutrition. Annu Rev Nutr 14:269-296.